Federal Science and Technology Grants

This funding opportunity provides financial support for U.S. organizations to host workshops, symposiums, and conferences that advance research and collaboration in space and Earth sciences and technology.

This funding opportunity supports U.S. institutions conducting research to enhance the understanding of tropical cyclones and precipitation processes using satellite data from a constellation of small satellites.

The "Privacy-Preserving Data Sharing in Practice" grant aims to fund research and development projects that create practical, scalable technologies for sharing data in a way that preserves privacy, with a focus on advancing privacy-enhancing technologies for artificial intelligence, developing tools and testbeds for safe data sharing, and promoting the usability and inclusiveness of these solutions.

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at sara@nasa.gov, but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

This grant invites academic institutions and researchers to propose innovative technologies and research projects that support the Navy's development and evaluation efforts, with a focus on engaging students and fostering the next generation of scientists and engineers.

This grant provides funding for organizations to assist the U.S. Army Corps of Engineers in managing cultural and natural resources at military installations in Hawaii, ensuring compliance with environmental and historic preservation laws.

The United States Agency for International Development (USAID) is seeking applications from all eligible organizations to implement the project, Promoting Impact and Learning with Promoting Impact and Learning with Cost-Effectiveness Evidence (PILCEE). USAID seeks qualified organizations to proactively and intentionally advance inclusive development to ensure the participation and inclusion of all people in programming, including those who have been historically marginalized. Please refer to the Program Description for the goals and expected results. Eligibility for this award is open to all eligible organizations. The authority for this RFA is found in the Foreign Assistance Act of 1961, as amended. USAID intends to award a single Leader with Associate Award (LWA) to the applicant(s) who best meets the objectives of this worldwide activity. A LWA is a cooperative agreement that covers a specified worldwide activity. Funding for this opportunity will be based on the merit review criteria described in this NOFO subject to a risk assessment. Eligible parties interested in submitting an application are encouraged to read this NOFO thoroughly to understand the type of program sought, application submission requirements and selection process. USAIDs independent Office of the Chief Economist (OCE) supports the Agency in bringing strong economic theory, evidence, and tools to bear to improve the Agencys programmatic effectiveness and broader global engagement. Two of the Offices strategic objectives are promoting the use of existing cost-effectiveness evidence in Agency decision-making and the generation of new cost-effectiveness evidence to fill important evidence gaps. Please see the Full OCE Promoting Impact and Learning with Cost-Effectiveness Evidence (PILCEE) Activity RFA under the "Related Documents" tab.

The Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) and the Air Force Office of Scientific Research (AFOSR) plan to jointly support foundational mathematical and statistical research on Digital Twins in applied sciences. Recent years have witnessed a significant increase in the demand and interest in applications that involve collaborative teams developing and analyzing Digital Twins to support decision making in various fields, including science, engineering, medicine, urban planning, and more. Both agencies recognize the need to promote research aiming to stimulate an interplay between mathematics/statistics/computation and practical applications in the realm of Digital Twins. This program encourages new collaborative efforts within the realm of Digital Twins, aiming at stimulating fundamental research innovation, pushing, and expanding the boundaries of knowledge, and exploring new frontiers in mathematics and computation for Digital Twin development, and its applications. By leveraging this synergy, the program aims to harness science, technology, and innovation to address some of our Societys most pressing challenges.

This grant provides funding for long-term ecological research at designated sites to enhance our understanding of ecosystems and their dynamics over time, primarily aimed at researchers and institutions in the field of ecology.

The Program supports research on the sources, sinks, transport, and transformation of gases and aerosols in the atmosphere through models, observations, and experiments, including homogeneous and heterogeneous chemical reactions, emissions, deposition, atmospheric oxidation and photochemistry, aqueous-phase chemistry and aerosol processes; the formation of new particles and secondary organic aerosols, the modeling of atmospheric chemical processes, the study of chemical mechanisms in the atmosphere, optical properties of gases and aerosols, and improved methods for measuring the concentrations of trace species and their fluxes into and out of the atmosphere.The Program encourages principal investigators from a wide variety of institutions and backgrounds to submit proposals.

This funding opportunity supports innovative research on rare cancers, providing up to $490,000 for early-stage projects that aim to improve diagnosis, understanding, and treatment, particularly benefiting military service members, veterans, and the general public.

This funding opportunity provides financial support to nonprofit organizations and higher education institutions for initiatives that improve earthquake safety and awareness across multiple states or nationally.

This is a Request for Information (RFI) only. This RFI is not accepting applications for financial assistance. The purpose of this RFI is solely to solicit input for ARPA-E consideration to inform the possible formulation of future programs. The purpose of this Request for Information (RFI) is to solicit input for a potential ARPA-E program focused on the development of technologies to recover high energy-value materials from wastewater to reduce energy demands and greenhouse gas (GHG) emissions associated with conventional sourcing and waste stream treatment. Wastewater in this RFI is broadly defined, and includes municipal, livestock, industrial, and mining sources. High energy-value materials under consideration are nutrients (i.e., ammonia and phosphorus) and critical minerals, where the latter are a group of 50 elements in the periodic table including lithium and rare earth elements (REEs). To view the RFI in its entirety, please visit https://arpa-e-foa.energy.gov.

This funding opportunity is designed to support partnerships among industry, government, and academia in developing and testing innovative mining technologies to strengthen the U.S. supply chain for critical minerals essential for energy and national security.

This grant provides funding to non-profit organizations in the U.S. and Ukraine to establish and strengthen partnerships between cities, promoting economic development, innovation, and cultural exchange in support of Ukraine's recovery and democratic growth.

This funding opportunity is designed for U.S.-based research institutions to advance the measurement of exoplanet masses, enhancing our understanding of their characteristics and formation processes.

The OCRP seeks to advance ovarian cancer research through development of early-career investigators. The OCRP Ovarian Cancer Academy (OCA) is a unique, interactive environment providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty to move ovarian cancer research into a new frontier. The overarching goal of the OCA is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment to enhance quality and expand quantity of the ovarian cancer research field.

This grant provides funding to U.S.-based organizations, including universities and companies, to develop innovative technologies that enhance plant engineering for sustainable energy and bioenergy production.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.